An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited announced an update regarding its ongoing share buy-back program. As of March 24, 2025, the company has repurchased a total of 1,688,181 ordinary fully paid securities, including 37,490 securities bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: -11.59%
Average Trading Volume: 720
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
Learn more about NEU stock on TipRanks’ Stock Analysis page.